Serum C‐reactive Protein Levels in Disease*

Morley, John J.; Kushner, Irving

doi:10.1111/j.1749-6632.1982.tb22153.x

Cited by 378 publications

(187 citation statements)

References 32 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…CRP levels have been used clinically to gauge the presence and extent of inflammation, as well as to evaluate the effectiveness of anti-inflammatory therapy, mainly in rheumatoid diseases (18). The major finding in this area was the strong association between marked increases in serum CRP concentrations (over 100 mg/l) and severe bacterial infections (32).…”

Section: Discussionmentioning

confidence: 99%

Levels of C-reactive protein in serum samples from healthy children and adults in São Paulo, Brazil

1997

Braz J Med Biol Res

View full text Add to dashboard Cite

C-reactive protein (CRP) was measured by ELISA in the sera of 165 healthy blood donors and 125 normal children 1 to 14 years old. The serum levels of blood donors ranged from 0.05 to 57.6 mg/l with median and mean values of 1.8 mg/l and 4.86 mg/l, respectively. CRP levels ranged from 0.02 to 14.4 mg/l in the children's sera, the median being 0.45 mg/l and the mean 1.65 mg/l. No individual lacking CRP was detected. The high CRP levels observed in the present study suggest that the population of the State of São Paulo may usually be exposed to subacute infections and/or inflammation without presenting clinical symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Levels of C-reactive protein in serum samples from healthy children and adults in São Paulo, Brazil

1997

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Around 50% of our study population was administered with β-blockers. B-blockers significantly decreased the levels of CRP of test population [13]. As we know that hypertension is also associated with inflammation so antihypertensive medication also has anti-inflammatory effects.…”

Section: 65%mentioning

confidence: 99%

Medicinal Efficacy of Antihypertensive Agents for Acute Inflammation; An Associated Risk Factor of Hypertension

Sarwar¹,

Subhani²,

Bilal³

et al. 2017

Matrix sci. medica

View full text Add to dashboard Cite

Hypertension is a lasting therapeutic complaint which can be kept in control by changing one's dietary and lifestyle habits. Present study is based on identification of risk of acute pancreatitis which may occur with different doses of atenolol in Pakistani population. About 50% of our study population was administered with β-blockers. The β-blockers significantly decreased the levels of CRP (C-Reactive Protein) of test population. This observation strongly depicts high potential of beta blockers in stabilization of CRP levels and decreasing inflammatory response. In our study the patients were administered with many combinations with beta-blocker and their results showed that these combinations lower the CRP level in hypertensive patients. We conclude that antihypertensive also minimize the inflammation associated hypertension but not completely, as inflammation was reversed only in 67.5% population who were using beta-blocker. When treating hypertension, anti-inflammatory medicine treatment needs to be endorsed to successfully treat complaints and increase the communal and psychosomatic status of the patient.

show abstract

“…Conversely, those proteins whose plasma concentrations decrease by at least twenty-five percent are termed negative acute phase proteins (Morley and Kushner, 1982). As specified by Pearson et al (2003) CRP elicits numerous reactions such as complement activation, accelerated neutrophil phagocytosis and release of ORs, stimulation of adhesion molecules, production of tissue factor, and increases in platelet aggregation.…”

Section: C-reactive Protein (Crp)mentioning

confidence: 99%

Homocysteine and Malondialdehyde as Predictors of Restenosis Following Percutaneous Coronary Intervention

et al. 2006

View full text Add to dashboard Cite

Restenosis is one of the major adverse outcomes of Percutaneous CoronaryIntervention (PCI). Previous studies have shown conflicting reports for homocysteine as a predictor of restenosis following PCI. The conflicting reports may be due to oxidative factors (stimulation of polymorphonuclear leukocyte [PMNL]-induced reactive oxygen species generation, xanthine-xanthine oxidase, and arachidonic acid metabolism) other than homocysteine which could cause endothelial cell dysfunction leading to restenosis.Malondialdehyde (MDA), a lipid peroxidation product, is a marker for oxidative stress and is related to all oxidative factors. Therefore, it is possible that serum MDA may be a better predictor of restenosis than plasma homocysteine. The purpose of this study is to determine whether or not the pre-procedural serum MDA and plasma homocysteine levels are elevated in patients who develop restenosis post PCI.The study included fifty-one patients undergoing elective PCI who consented to participate in a protocol that was approved by the Ethics Committee of the University of Saskatchewan. Homocysteine and malondialdehyde were measured in the plasma and serum respectively. Blood samples were collected pre-procedural, 0 time, 8 hours, 24 hours, and 6 months post-procedure. Exercise tolerance tests were performed at two weeks, and six months post-procedure to determine if there was any evidence of restenosis.The results of the study showed that pre-procedural values of plasma homocysteine in the restenosis and non-restenosis groups were 10.37 ± 0.46 and 10.73 ± 0.49 respectively. These values were not significantly different (p=0.60) between the groups. The pre-procedural levels of plasma homocysteine were not significantly ii different (p=0.08) from the post-PCI values of those patients who did not develop restenosis at the 6-month time interval. However, the pre-procedural levels of plasma homocysteine were significantly different from the post-PCI values of those patients in the restenosis group at the 24hr (p=0.04) and 6-month (p=0.002) time intervals. In the restenosis group there was a significant increase (24%) after six months in the values of homocysteine from the pre-procedural levels. Thus, this indicates that restenosis is associated with higher post-PCI levels of homocysteine.The pre-procedural levels of serum MDA in the restenosis and non-restenosis groups were 0.124± 0.16 and 0.147± 0.02 respectively. There was no significant difference (p=0.60) between the two groups. There was also no significant difference The results suggest that pre-procedural levels of plasma homocysteine and serum MDA were not predictors of restenosis following PCI. However, the post-PCI sixmonth levels of both homocysteine and MDA are predictors of restenosis. Moreover, the post-PCI levels of MDA were better predictors of restenosis than the post-PCI levels of homocysteine because the increase in MDA levels were greater at six months than the rise in homocysteine levels at the same time interval.iii ACKNOWLEDGEMENTS

show abstract

Serum C‐reactive Protein Levels in Disease*

Cited by 378 publications

References 32 publications

Levels of C-reactive protein in serum samples from healthy children and adults in São Paulo, Brazil

Levels of C-reactive protein in serum samples from healthy children and adults in São Paulo, Brazil

Medicinal Efficacy of Antihypertensive Agents for Acute Inflammation; An Associated Risk Factor of Hypertension

Homocysteine and Malondialdehyde as Predictors of Restenosis Following Percutaneous Coronary Intervention

Contact Info

Product

Resources

About